What was the market valuation of the US viral vector-manufacturing market in 2024?

The market valuation was $46.4 Million in 2024. Read More

What is the projected market valuation for the US viral vector-manufacturing market by 2035?

The projected valuation for 2035 is $270.73 Million. Read More

What is the expected CAGR for the US viral vector-manufacturing market during the forecast period 2025 - 2035?

The expected CAGR is 17.39% during the forecast period 2025 - 2035. Read More

Which application segment had the highest valuation in 2024?

The Vaccines segment had the highest valuation at $90.0 Million in 2024. Read More

Which end-use segment contributed the most to the market in 2024?

The Pharmaceutical Companies segment contributed the most, with a valuation of $106.25 Million. Read More

What is the valuation range for Gene Therapy in the application segment?

The valuation range for Gene Therapy is from $10.0 Million to $60.0 Million. Read More

How does the valuation of Single-Stranded vectors compare to Double-Stranded vectors?

Single-Stranded vectors have a valuation range of $18.0 Million to $108.0 Million, while Double-Stranded vectors range from $20.4 Million to $116.73 Million. Read More

Which company is a key player in the US viral vector-manufacturing market?

Sangamo Therapeutics is one of the key players in the market. Read More

What is the valuation range for the Oncology application segment?

The valuation range for the Oncology application segment is from $12.0 Million to $70.0 Million. Read More

US Viral Vector Manufacturing Market

Q: What are the key types of viral vectors in the market?

Key types include Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, and Retroviral Vectors. Read More

ID: MRFR/LS/13117-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Viral Vector Manufacturing Market Research Report: Size, Share, Trend Analysis By Applications (Gene Therapy, Vaccines, Oncology, Cardiovascular Diseases), By Types (Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors), By End Use (Pharmaceutical Companies, Research Institutions, Biotechnology Companies) and By Vector Design (Self-Complementary, Single-Stranded, Double-Stranded) - Growth Outlook & Industry Forecast 2025 To 2035

US Viral Vector Manufacturing Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Application (USD Million)
  1. 4.1.1 Gene Therapy
  2. 4.1.2 Vaccines
  3. 4.1.3 Oncology
  4. 4.1.4 Cardiovascular Diseases
2. 4.2 Security, Access Control and Robotics, BY Type (USD Million)
  1. 4.2.1 Adenoviral Vectors
  2. 4.2.2 Adeno-Associated Viral Vectors
  3. 4.2.3 Lentiviral Vectors
  4. 4.2.4 Retroviral Vectors
3. 4.3 Security, Access Control and Robotics, BY End Use (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Research Institutions
  3. 4.3.3 Biotechnology Companies
4. 4.4 Security, Access Control and Robotics, BY Vector Design (USD Million)
  1. 4.4.1 Self-Complementary
  2. 4.4.2 Single-Stranded
  3. 4.4.3 Double-Stranded
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Sangamo Therapeutics (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Adenoviral Vector Technologies (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GSK (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Viralgen (ES)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 CureVac (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY END USE
5. 6.5 US MARKET ANALYSIS BY VECTOR DESIGN
6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USE, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USE, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY VECTOR DESIGN, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY VECTOR DESIGN, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
  4. 7.2.4 BY VECTOR DESIGN, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Application (USD Million, 2025-2035)

Gene Therapy
Vaccines
Oncology
Cardiovascular Diseases

Security, Access Control and Robotics By Type (USD Million, 2025-2035)

Adenoviral Vectors
Adeno-Associated Viral Vectors
Lentiviral Vectors
Retroviral Vectors

Security, Access Control and Robotics By End Use (USD Million, 2025-2035)

Pharmaceutical Companies
Research Institutions
Biotechnology Companies

Security, Access Control and Robotics By Vector Design (USD Million, 2025-2035)

Self-Complementary
Single-Stranded
Double-Stranded

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”